NIHR Impact Prize 2025: The STAMPEDE Trial

A multi arm platform trial to assess 10 different treatment approaches in men with advanced prostate cancer, leading to improvements in survival

The findings of STAMPEDE have led to extended survival rates for men with advanced prostate cancer. They have changed global treatment guidelines and shed new light on long-term outcomes, including new indicators of treatment response, better targeting of therapies and interventions reducing complications.

Supported by NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and NIHR Research Delivery Network.

Comments from the judging panel: “A study with clear evidence of global impact. It has impacted economic growth, saved lives and influenced policy, while also supporting the design of other studies.”